H.C. Wainwright on Senti Biosciences, Inc. (SNTI): FDA Alignment and Mid-2026 Durability Data in Focus
Tweet Send to a Friend
H.C. Wainwright analyst Emily Bodnar reiterated a Buy rating and $12.00 price target on Senti Biosciences, Inc. (NASDAQ: SNTI)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
